ScholarLens Back to search
1979•PubMedRequires access

A comparison of sulindac with ibuprofen in the management of rheumatoid arthritis.

Burry Hc, L Witherington

Open publisher page 4 citations

Abstract

Sulindac 200mg b.i.d. was compared with ibuprofen 400mg t.d.s. in a double-blind controlled trial in patients with rheumatoid arthritis. Both drugs produced a measurable and significant improvement from baseline levels, in both objective and subjective parameters. All parameters favoured sulindac but the differences were not statistically significant. Side effects were infrequent with both drugs and in all but three cases did not necessitate withdrawal from the trials. Sulindac appears to be an effective anti-inflammatory analgesic drug for the management of rheumatoid arthritis with a low incidence of side effects.

About this research paper

What this paper is about

Sulindac 200mg b.i.d. was compared with ibuprofen 400mg t.d.s. in a double-blind controlled trial in patients with rheumatoid arthritis. Both drugs produced a measurable and significant improvement from baseline levels, in both objective and subjective parameters. All parameters favoured sulindac but the differences were not statistically significant. Side effects were infrequent with both drugs and in all but three cases did not necessitate withdrawal from the trials. Sulindac appears to be an effective anti-inflammatory analgesic drug for the management of rheumatoid arthritis with a low incidence of side effects.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Sulindac 200mg b.i.d. was compared with ibuprofen 400mg t.d.s. in a double-blind controlled trial in patients with rheumatoid arthritis. Both drugs produced a measurable and significant improvement from baseline levels, in both objective and subjective parameters. All parameters favoured sulindac but the differences were not statistically significant. Side effects were infrequent with both drugs and in all but three cases did not necessitate withdrawal from the trials. Sulindac appears to be an effective anti-inflammatory analgesic drug for the management of rheumatoid arthritis with a low incidence of side effects.

Key concepts: Sulindac, Medicine, Ibuprofen, Rheumatoid arthritis, Analgesic, Incidence (geometry), Drug, Nonsteroidal

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
A comparison of sulindac with ibuprofen in the management of rheumatoid arthritis. — Research Paper | ScholarLens